{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:30:33Z","timestamp":1787783433962,"version":"build-2784847793"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>There is limited information on the clinical use of Janus kinase inhibitors (JAKis) for rheumatoid arthritis treatment in Japan. The aim of this study was to identify disease-modifying antirheumatic drug (DMARD) treatment patterns in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective, longitudinal study extracted data from the Japan Medical Data Center database. Patients with rheumatoid arthritis diagnosis were enrolled 2016\u201319, during which patients had a first prescription of a major DMARD, split into six mutually exclusive classes: methotrexate (MTX); other conventional synthetic DMARDs; tumour necrosis factor alpha inhibitors; cytotoxic T-lymphocyte-associated antigen-4-immunoglobulin; anti-interleukin-6 receptor therapies; and JAKis. The primary objective was to describe DMARD treatment patterns, especially for JAKis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 10,399 patients were included in the analysis. The most common treatments were MTX, other conventional synthetic DMARDs, and tumour necrosis factor alpha inhibitors. The total number of JAKi prescriptions increased approximately 8-fold during 2016\u201319. Most (61.1%) patients who received JAKis had prior MTX or tumour necrosis factor alpha inhibitor treatment. The duration of JAKi treatment was longer than for biologics and other conventional synthetic DMARDs and comparable to that of MTX.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The sequence of drug class prescriptions for rheumatoid arthritis in Japan during 2016\u201319 followed clinical guidelines. Over this period, JAKis were increasingly used as a second-line treatment following MTX.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac046","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T20:01:34Z","timestamp":1654027294000},"page":"448-459","source":"Crossref","is-referenced-by-count":8,"title":["A retrospective, longitudinal study of rheumatoid arthritis treatment patterns with Janus kinase inhibitors and other disease-modifying antirheumatic drugs in Japan"],"prefix":"10.1093","volume":"33","author":[{"given":"Yuko","family":"Kaneko","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snijder","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd , Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kokubo","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-4319","authenticated-orcid":false,"given":"Daisuke","family":"Kato","sequence":"additional","affiliation":[{"name":"Astellas Pharma Inc. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"2023092217015784900_R1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","article-title":"Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey","volume":"30","author":"Kojima","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023092217015784900_R2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023092217015784900_R3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3904\/kjim.2015.137","article-title":"Current concepts in the management of rheumatoid arthritis","volume":"31","author":"Tanaka","year":"2016","journal-title":"Korean J Intern Med"},{"key":"2023092217015784900_R4","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2020.1739649","article-title":"Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials","volume":"21","author":"Tanaka","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"2023092217015784900_R5","article-title":"Law No. 57 of 2003. Law Concerning Protection of Personal Information","author":"Government of Japan","year":"2003"},{"key":"2023092217015784900_R6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023092217015784900_R7","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2023092217015784900_R8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40261-021-01082-x","article-title":"Prescribing trends of biologic disease-modifying anti-rheumatic drugs using a claims database from 6 million people in Japan","volume":"41","author":"Hirata","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2023092217015784900_R9","first-page":"1032","article-title":"Bootstrapping the Kaplan\u2013Meier estimator","volume":"81","author":"Akritas","year":"1986","journal-title":"J Am Stat Assoc"},{"key":"2023092217015784900_R10","first-page":"1351","article-title":"Clinical practice guidelines 2020 for the management of rheumatoid arthritis","volume":"79","author":"Kawahito","year":"2021","journal-title":"Nihon Rinsho"},{"key":"2023092217015784900_R11","first-page":"485","article-title":"Real-world experience with tofacitinib for the treatment of rheumatoid arthritis","volume":"37","author":"Caporali","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2023092217015784900_R12","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab126","article-title":"Trend in prescription and treatment retention of molecular-targeted drugs in 121,131 Japanese patients with rheumatoid arthritis: a population-based real-world study","author":"Takabayashi","year":"2021","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac046\/43993368\/roac046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/448\/51715200\/roac046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/3\/448\/51715200\/roac046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T17:33:01Z","timestamp":1695403981000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/3\/448\/6594189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,5,27]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac046","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,5,27]]}}}